A detailed history of Quantbot Technologies LP transactions in Axogen, Inc. stock. As of the latest transaction made, Quantbot Technologies LP holds 11,784 shares of AXGN stock, worth $217,179. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,784
Holding current value
$217,179
% of portfolio
0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.52 - $14.69 $88,615 - $173,106
11,784 New
11,784 $165,000
Q4 2023

Feb 14, 2024

BUY
$3.61 - $7.76 $14,909 - $32,048
4,130 New
4,130 $28,000
Q2 2023

Aug 08, 2023

BUY
$8.5 - $10.38 $3,400 - $4,152
400 New
400 $3,000
Q4 2022

Feb 13, 2023

BUY
$9.44 - $13.09 $27,366 - $37,947
2,899 New
2,899 $28,000
Q2 2022

Aug 09, 2022

SELL
$6.99 - $10.0 $15,965 - $22,840
-2,284 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$7.26 - $10.7 $30,492 - $44,940
-4,200 Reduced 64.77%
2,284 $18,000
Q4 2021

Feb 11, 2022

BUY
$8.8 - $16.0 $51,920 - $94,400
5,900 Added 1010.27%
6,484 $60,000
Q3 2021

Nov 09, 2021

SELL
$15.23 - $21.72 $56,594 - $80,711
-3,716 Reduced 86.42%
584 $9,000
Q2 2021

Aug 12, 2021

BUY
$17.8 - $23.5 $76,540 - $101,050
4,300 New
4,300 $92,000
Q4 2020

Feb 12, 2021

SELL
$11.5 - $17.96 $4,600 - $7,184
-400 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$10.62 - $13.12 $4,248 - $5,248
400 New
400 $4,000
Q3 2019

Nov 12, 2019

SELL
$12.09 - $20.46 $194,649 - $329,406
-16,100 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$18.5 - $25.47 $297,850 - $410,067
16,100 New
16,100 $318,000
Q1 2019

May 13, 2019

SELL
$14.62 - $22.13 $366,962 - $555,463
-25,100 Closed
0 $0
Q4 2018

Feb 13, 2019

BUY
$17.09 - $38.25 $428,959 - $960,075
25,100 New
25,100 $512,000
Q1 2018

May 11, 2018

SELL
$24.4 - $40.25 $110,898 - $182,936
-4,545 Closed
0 $0
Q4 2017

Feb 12, 2018

BUY
$18.5 - $28.6 $84,082 - $129,987
4,545
4,545 $128,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $779M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Quantbot Technologies LP Portfolio

Follow Quantbot Technologies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

News

Stay updated on Quantbot Technologies LP with notifications on news.